MPM BioImpact — Full Portfolio

Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.

BiotechHealthtechBoston, US

NSNatarajan Sethuraman(Executive Officer)inNKNerissa Kreher(Executive Officer)inKWKory Wentworth(Executive Officer)inDDDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)NJNathan J. Dowden(President and Chief Operating Officer)in

Board seatTFTodd Foley· per SEC Form D

Co-investors5A5AM VenturesAGAgent CapitalMRMRL Ventures FundRORoche Venture FundTCTCG CrossoverWEWellington Management

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOBOxana Beskrovnaya, Ph.D.(Executive Officer)JGJohn G. Cox(President and Chief Executive Officer)in

Co-investorsATAtlas VentureHEHercules Capital, Inc.VIVida VenturesWEWellington ManagementFOForbionRARA Capital

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inAMArlene Morris(Executive Officer, Director)inMAMichael A. Metzger(Chief Executive Officer)inKAKeith A. Goldan(Chief Financial Officer)in

BoardDPDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsAIAisling CapitalATATEM Capital FundAVAvoro Capital AdvisorsBIBioBritDEDelos CapitalECEcoR1 Capital+6 more

Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.

BiotechHealthtechSeattle, US

AMAndrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)Andrew Scharenberg(Founder)Michael Jensen(Founder)Philip Low(Founder)Ryan Crisman(Founder)

Board seatLELuke Evnin· per SEC Form D

Co-investorsDCDCVC BioQIQiming Venture Partners USASOSoftBank GroupK2K2 HealthVenturesSOSoftBank Vision FundALAlexandria+2 more

Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.

BiotechHealthtechLa Jolla, US

PFPeter Flynn, Ph.D.(Executive Officer, Director)

BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)TRTighe Reardon(Executive Officer)

Co-investorsAVAvalon BioVenturesCACatalys Pacific

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.

BiotechHealthtechLongevity

GMGeoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)

Co-investorsVEVersant VenturesDCDCVC BioLILilly Asia VenturesDCDCVC (Data Collective)

Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.

BiotechHealthtechLongevityWaltham, US

Amit Choudhary(Scientific Founder)DSDavid Steinberg(Chairman & Founding CEO)inEHEdward Holson(Co-founder & CSO)inLNLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in

Co-investorsLOLongwood Fund8V8VCMRMRL Ventures FundONOno Venture Investment, Inc.

Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.

AI & Machine LearningBiotechHealthtech

VKVijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)COChristine O'Brien(Chief Executive Officer & Board Member)inCBCourtney Beers(Chief Scientific Officer)

Co-investorsCACanaan PartnersABAbingworthGIGilead SciencesASAstellas Venture Management LLCLILightstone Ventures

Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.

BiotechHealthtech

ASAnil Singhal(President and CEO)inSMSiddhartha Mitra(Chief Medical Officer)in

Co-investorsCACanaan PartnersASAstellas Venture Management LLCLILightstone Ventures

Vascular Pharmaceuticals develops VPI-2960B, a therapeutic candidate in clinical development for diabetic nephropathy treatment.

BiotechDigital HealthMedical DevicesChapel Hill, US

Laura Maile(Co-Founder, Director, Research and Development)RSRichard Shea(Executive Officer, Director)inBonnie Layman(Executive Officer)David Clemmons(Co-Founder, Chief Scientific Officer)

BoardESElizabeth Stoner(Director)inRichard Kent(Director)

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)inTTTodd T. Foley(Director)inVincent Miles(Director)AKAnsbert K. Gadicke(Director)in

Board seatBard GeesamanDavid StackAGAnsbert Gadicke· per SEC Form D

Co-investorsHEHEALTHCARE ROYALTY PARTNERSSOSofinnova VenturesABAbingworthARARCH Venture Partners

Clinicalink offers a digital tool designed to improve drug adherence and measure the functional quality of weight loss.

Digital HealthHealthtechSaaSWinston-Salem, US

Douglas E. Pierce, Jr.(Executive Officer, Director, Promoter)Joe Schmidt(Executive Officer)Edward S. Seguine(Executive Officer, Director, Promoter)

BoardMKMatt King(Director)inBrad Geesaman(Director)

Board seatTRTony RosenbergTFTodd FoleyAGAnsbert Gadicke· per SEC Form D

Co-investorsFCFCA Venture PartnersMCMcKesson Ventures

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDWDmitri Wiederschain(Executive Officer)in

BoardACAlexandra Cantley(Director)inSakae Asanuma(Director)inBMBriggs Morrison(Executive Officer, Director, Promoter)inIMIrena Melnikova(Director)in

Board seatTFTodd Foley· per SEC Form D

Co-investorsLILifelinkPFPfizer Venture InvestmentsBIBiotechnology Value FundMIMirae Asset Venture InvestmentPFPfizer VenturesPOPolaris Partners+1 more

Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.

AI & Machine LearningBiotechSouth San Francisco, US

CVChris Varma, Ph.D.(Executive Officer, Director)CVChris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)JHJohannes Hermann, Ph.D.(Executive Officer)KWKevin Webster(Executive Officer)inGregory Chow(Executive Officer)

Board seatLELuke Evnin· per SEC Form D

Co-investorsBEBerkeley CatalystDCDCVC (Data Collective)DRDroia VenturesFEFelicis VenturesRARA CapitalDCDCVC Bio+2 more

A research-intensive biopharmaceutical company that develops medicines and vaccines.

BiotechHealthtechSouth San Francisco, US

Luke Nathaniel Walker(Executive Officer)JEJulie Eastland(Executive Officer, Director)in

BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)

Board seatPBPatrick BaeuerleLELuke EvninPablo CagnoniDan Hicklin· per SEC Form D

Co-investorsK2K2 HealthVenturesRIRidgeback CapitalTATaiho Ventures, LLCARArix BioscienceLILilly Asia VenturesNENew Leaf Venture Partners+1 more

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

GFGordon Freeman(Scientific Founder)XZXingXing Zang(Scientific Founder)inICIvan Cheung(Chief Executive Officer)inLGLeena Gandhi(Chief Medical Officer)inTNTatiana Novobrantseva(Chief Scientific Officer)inAHAxel Hoos(Director)

Board seatDBDetlev Biniszkiewicz· per SEC Form D

Co-investorsCACatalio Capital Management, LPSASanofi VenturesCACatalio Capital ManagementINInvusLELeaps by BayerSISixty Degree Capital

Cambridge, US

CQChristophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)CWCameron Wheeler(Director)in

Board seatMitchell FinerLELuke EvninBMBriggs Morrison· per SEC Form D

Co-investorsASAstellas Venture Management LLCCOCowen Healthcare InvestmentsDEDeerfield Management CompanyIMIMM InvestmentK2K2 HealthVenturesSPSphera Funds Management

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.

BiotechDigital HealthMental HealthMorristown, US

Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)ELEllen Lubman(Director)MPMark Pollack(Executive Officer)inNBNathan Bryson(Executive Officer)inMTMark Theeuwes(Executive Officer)in

Board seatAGAnsbert Gadicke· per SEC Form D

Co-investorsFEFemHealth VenturesMIMitsui Global InvestmentPAPalo Santo VCNONovo Holdings

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.

BiotechHealthtechMedical DevicesWatertown, US

Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)LELuke Evnin(Co-founder, Board member (Chairman))inDavid Cordo(Executive Officer)Alon Lazarus(Director)

BoardCWChristoph Westphal(Director)

Board seatLELuke EvninBMBriggs Morrison· per SEC Form D

Co-investorsDCDC Investment PartnersK2K2 HealthVenturesLOLongwood FundRARA CapitalTATaiho Ventures, LLCUPUPMC Enterprises

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

IGIlan Ganot(CEO)inBMBenit Maru(CMO)MVMatthias Van Woensel(CSO)in

Co-investorsDRDroia VenturesFRFrazier Life SciencesNONovartis Venture FundRVRV Invest GmbHFRFrazier Healthcare PartnersRTRTW Investments L.P.+1 more

Co-investorsVEVersant VenturesVIVivo Capital

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

KYKarl Y. Hostetler(Executive Officer, Director)inGMGail Maderis(Director)inKBKristine Ball(President & CEO)inECElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRGRaju Gadiraju(Executive Officer)in

Co-investorsADAdjuvant CapitalAVAvestria VenturesBRBrace PharmaCACanaan PartnersGAGaingelsGVGV (Google Ventures)+6 more

The company develops therapies for people with severe autoimmune diseases.

BiotechHealthtechMedical Devices

Co-investorsAVAvoro Capital AdvisorsBIBioGeneration VenturesHBHBM Healthcare InvestmentsOMOmnes CapitalPMPMVSESeventure Partners+3 more

āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers.

BiotechHealthtechBurlingame, US

PBPankaj Bhargava(Founder & Chief Executive Officer)inVSVictoria Smith(Chief Scientific Officer)DWDeborah Wenkert(Chief Medical Officer)inJSJoseph Sarret(Acting Chief Operating Officer)BSBrian Shuster(Acting Chief Business Officer)

Co-investorsAGAgent Capital

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

JRJane Rhodes(Chief Executive Officer)inMIMagnus Ivarsson(Chief Scientific Officer)inHPHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

Co-investorsBRBrandon CapitalDEDementia Discovery FundNONovartis Venture FundSVSV Health InvestorsUCUCL Technology FundALAlbionVC

Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.

BiotechDigital Health

Co-investorsLALAVLILilly Asia VenturesSCSchooner CapitalTATaiho Ventures, LLC

BiotechGermantown, US

JMJohn Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)

BoardLHLu Han(Director)in

Co-investorsATATEM Capital FundLULumira VenturesPLPlains VenturesECEcho Investment CapitalLELeaps by Bayer

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.

BiotechDeep TechHealthtechWaltham, US

DHDavid Hallal(CEO)inMPMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in

Co-investorsECEcoR1 CapitalSASamsara BioCapitalSOSoftBank Vision Fund

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

ALAnn Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSBSamuel Bjork(Director)inACAlexandra Cantley(Director)inSMSeiji Miyahara(Director)in

Co-investorsAVAvego BioScience CapitalGVGV (Google Ventures)MIMission BiocapitalNONovartis Venture FundRORoche Venture FundSASamsara BioCapital+4 more

Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development.

BiotechHealthtechMedical Devices

Scott Hirsch(CEO)inDan Kaplan(CSO)

Co-investorsDEDecheng Capital

Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.

Co-investorsLALatterell Venture PartnersTHThe Vertical GroupOROrbiMedVEVersant Ventures

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

AWAmanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

BoardLBLaura Brass(Director)inKWKai Wucherpfennig(Director)

Co-investorsAGAgent CapitalDCDC Investment PartnersLILifelinkLOLongwood FundM M VenturesMEMedical Excellence Capital+5 more

K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials.

BiotechHealthtech

Ying Huang, Ph.D.(Chief Executive Officer, Director)

Co-investorsALAlpine Space VenturesALAltimeter CapitalCACapitalGICICONIQKLKleiner PerkinsLILightspeed Venture Partners+4 more

The page is an online gambling/betting operator ("OK9") targeting Vietnamese players, offering sports betting, online casino, slots, fish-shooting games, lottery, and card games.

Deep TechHardwareSpace TechWest Hollywood, US

Neeldev Kunjur(Executive Officer, Director)Karandev Kunjur(Executive Officer, Director)KKKaran Kunjur(Founder)inNKNeel Kunjur(Founder)in

Co-investorsALAlpine Space VenturesALAlso CapitalASAsymmetric Capital PartnersCACapitalGEAEarthrise VenturesFIFirst Round Capital+22 more

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.

AI & Machine LearningBiotechMedical Devices

JBJoe Bolen(Chief Executive Officer)JBJoe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)CLCiaran Lawlor, Ph.D.(Chief Operating Officer)FNFrank Neumann, M.D., Ph.D.(Chief Medical Officer)SSSiva Sakhamuri(Chief Technology Officer)in

Co-investorsASAstellas Venture Management LLCTATaiho Ventures, LLC

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

BJBrent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDRDroia VenturesNONovartis Venture FundDIDigitalis VenturesFOForbionLILightspeed Venture PartnersVIVida Ventures+1 more

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAJAju IB InvestmentECEcoR1 CapitalEVEvolution VC PartnersOROrbiMedOUOUP (Osage University Partners)PFPfizer Venture Investments+6 more

BiotechOklahoma City, US

Scott Rollins, Ph.D.(Executive Officer, Director)David Falconer(Executive Officer)inRichard Alvarez(Executive Officer)inRussell Rother(Executive Officer)inRodger McEver, M.D.(Director)

BoardPhilip Jones, M.D.(Director)

Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.

BiotechCambridge, US

Robert Millman(Executive Officer, Director)

BoardTFTodd Foley(Executive Officer, Director)inMitch Finer(Director)SKStephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)

Co-investorsARARCH Venture PartnersF-F-Prime CapitalJDJDRF T1D FundORORI CapitalSLSlater Technology Fund6 6 Dimensions Capital+4 more

SiO2 Materials Science develops precision molded polymer containers with thin glass-like barrier coatings for pharmaceutical and biopharmaceutical applications.

BiotechMedical DevicesNew MaterialsAuburn, US

Robert S. Abrams(Executive Officer, Director)inRobert Pangborn(Director)John Belfance(Director)Jean-Marie Painvin(Director)Thomas Strungmann(Director)Jared Morris(Director)

An Italian-language affiliate guide that reviews and ranks non-AAMS online casinos (foreign-licensed gambling sites) accessible to Italian players, comparing bonuses, game catalogs, payment methods, and licensing.

ConsumerGamingMedia & EntertainmentBridgewater, US

WDWilliam Duke(Executive Officer)inKPKristine Peterson(Executive Officer, Director)

BoardDaniel Pelak(Director)Sean Traynor(Director)IHIttai Harel(Director)inPaul Queally(Director)

Co-investorsAGAgate Medical Investments LPHLHLM Investment PartnersKAKaiser Permanente VenturesABAbingworthPIPitangoWEWelsh, Carson, Anderson & Stowe